Phase Ib Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330), Gemcitabine and Nab-Paclitaxel and Phase II Study of Gemcitabine and Selinexor in Patients With Metastatic Pancreatic Cancer
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 15
- 试验地点
- 2
- 主要终点
- Maximum Tolerated Dose (MTD) of Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-stabilized Nanoparticle Formulation Combination (Phase Ib)
研究概览
简要总结
This partially randomized phase Ib/II trial studies the side effects and best dose of selinexor when given together with gemcitabine and nab-paclitaxel, and to see how well they work in treating patients with pancreatic cancer that has spread to other parts of the body (metastatic). Drugs used in chemotherapy, such as selinexor, gemcitabine and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
详细描述
Primary Objectives:
- Phase I: To determine the recommended phase 2 dose (RP2D) of gemcitabine, nabpaclitaxel and selinexor for untreated metastatic pancreatic cancer [COMPLETED]
- Phase I: To determine the safety profile of gemcitabine, nab-paclitaxel and selinexor [COMPLETED]
- Phase II: To test whether the combination of gemcitabine and selinexor improves the median overall survival of patients with metastatic pancreatic cancer who have failed frontline non-gemcitabine containing regimens beyond 5.6 months (median overall survival of patient receiving gemcitabine only based on historical data.
Secondary Objectives:
- To determine objective response rate to the combination of gemcitabine and selinexor using Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
- To assess safety of selinexor in combination with gemcitabine in phase II portion of the study
- To determine progression free survival (PFS) in patients treated with gemcitabine and selinexor
- To determine the influence of selinexor and gemcitabine on the nuclear expression and localization of tumor suppressor gene proteins.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent in accordance with federal, local, and institutional guidelines
- •Patients with metastatic pancreatic adenocarcinoma not treated with chemotherapy for metastatic disease
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- •Absolute neutrophil count (ANC) >= 1500/mm^3
- •Platelet count >= 100,000/mm^3
- •Bilirubin < 2 times the upper limit of normal (ULN) (except patients with Gilbert's syndrome who must have a total bilirubin of < 3 times ULN)
- •Alanine aminotransferase (ALT) < 2.5 times ULN
- •Serum creatinine =< 1.5 mg/dL
- •Serum albumin >= 3.0 g/dL
- •Female patients of child-bearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at screening, and male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential; acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal; for both male and female patients, effective methods of contraception must be used throughout the study and for three months following the last dose
- •Patients with history of previously treated malignancies who have no evidence of disease for last five years are allowed to participate
排除标准
- •Patients who are pregnant or lactating
- •Radiation, chemotherapy, or immunotherapy or any other anticancer therapy =< 3 weeks prior to cycle 1 day 1; mitomycin C or radio-immunotherapy 6 weeks prior to cycle 1 day 1
- •Major surgery within four weeks before cycle 1 day 1
- •Unstable cardiovascular function:
- •Symptomatic ischemia, or
- •Uncontrolled clinically significant conduction abnormalities (e.g.: ventricular tachycardia on antiarrhythmics are excluded and 1st degree atrioventricular [AV] block or asymptomatic left anterior fascicular block [LAFB]/right bundle branch block [RBBB] will not be excluded), or
- •Congestive heart failure (CHF) of New York Heart Association (NYHA) class >= 3, or
- •Myocardial infarction (MI) within 3 months of cycle 1 day 1 dose
- •Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose
- •Known to be HIV seropositive who are on anti-HIV drugs because of the unknown interactions between these drugs and the study agents
- •Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus (HCV) ribonucleic acid (RNA) or HBsAg (hepatitis B virus [HBV] surface antigen)
- •Patients with active central nervous system (CNS) malignancy; asymptomatic small lesions are not considered active; treated lesions may be considered inactive if they are stable for at least 3 months
- •Patients with significantly diseased or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea
- •Grade >= 2 peripheral neuropathy within 14 days prior to cycle 1 day 1
- •History of seizures, movement disorders or cerebrovascular accident within the past 5 years prior to cycle 1 day 1
- •Patients with muscular degeneration, uncontrolled glaucoma, or markedly decreased visual acuity based on physician's assessment
- •Serious psychiatric or medical conditions that could interfere with treatment
- •Participation in an investigational anti-cancer study within 3 weeks prior to cycle 1 day 1
- •Concurrent therapy with approved or investigational anticancer therapeutic
- •Presence of clinically significant ascites
研究组 & 干预措施
Group I: Phase Ib (gemcitabine, nab-paclitaxel, selinexor)
Patients receive gemcitabine hydrochloride IV, nab-paclitaxel IV, and selinexor PO on days 1, 8, and 15. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
干预措施: gemcitabine hydrochloride (Drug)
Group I: Phase Ib (gemcitabine, nab-paclitaxel, selinexor)
Patients receive gemcitabine hydrochloride IV, nab-paclitaxel IV, and selinexor PO on days 1, 8, and 15. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
干预措施: Selinexor (Drug)
Group I: Phase Ib (gemcitabine, nab-paclitaxel, selinexor)
Patients receive gemcitabine hydrochloride IV, nab-paclitaxel IV, and selinexor PO on days 1, 8, and 15. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
干预措施: Pharmacological Study (Other)
Group I: Phase Ib (gemcitabine, nab-paclitaxel, selinexor)
Patients receive gemcitabine hydrochloride IV, nab-paclitaxel IV, and selinexor PO on days 1, 8, and 15. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
干预措施: Laboratory Biomarker Analysis (Other)
Group I: Phase Ib (gemcitabine, nab-paclitaxel, selinexor)
Patients receive gemcitabine hydrochloride IV, nab-paclitaxel IV, and selinexor PO on days 1, 8, and 15. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
干预措施: Nab paclitaxel (Drug)
Group II: Phase II Group I (gemcitabine, selinexor)
Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15. Patients also receive selinexor PO on days 3, 8, and 15 of cycle 1 and on days 1, 8, and 15 for the subsequent cycles. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
干预措施: gemcitabine hydrochloride (Drug)
Group II: Phase II Group I (gemcitabine, selinexor)
Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15. Patients also receive selinexor PO on days 3, 8, and 15 of cycle 1 and on days 1, 8, and 15 for the subsequent cycles. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
干预措施: Selinexor (Drug)
Group II: Phase II Group I (gemcitabine, selinexor)
Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15. Patients also receive selinexor PO on days 3, 8, and 15 of cycle 1 and on days 1, 8, and 15 for the subsequent cycles. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
干预措施: Pharmacological Study (Other)
Group II: Phase II Group I (gemcitabine, selinexor)
Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15. Patients also receive selinexor PO on days 3, 8, and 15 of cycle 1 and on days 1, 8, and 15 for the subsequent cycles. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
干预措施: Laboratory Biomarker Analysis (Other)
GroupIII: Phase II Group II (gemcitabine, selinexor)
Patients receive gemcitabine hydrochloride IV and selinexor PO on days 1, 8, and 15. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
干预措施: gemcitabine hydrochloride (Drug)
GroupIII: Phase II Group II (gemcitabine, selinexor)
Patients receive gemcitabine hydrochloride IV and selinexor PO on days 1, 8, and 15. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
干预措施: Selinexor (Drug)
GroupIII: Phase II Group II (gemcitabine, selinexor)
Patients receive gemcitabine hydrochloride IV and selinexor PO on days 1, 8, and 15. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
干预措施: Pharmacological Study (Other)
GroupIII: Phase II Group II (gemcitabine, selinexor)
Patients receive gemcitabine hydrochloride IV and selinexor PO on days 1, 8, and 15. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
干预措施: Laboratory Biomarker Analysis (Other)
结局指标
主要结局
Maximum Tolerated Dose (MTD) of Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-stabilized Nanoparticle Formulation Combination (Phase Ib)
时间窗: 28 days
MTD is defined as the lowest dose for which less than a third of patients experience a dose limiting toxicity graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Overall Survival (Phase II)
时间窗: Up to 7 months post treatment initiation
Estimated on an intention-to-treat basis (using all registered patients), and on a response-evaluable basis (using all patients who completed at least one 4-week treatment cycle) using the Kaplan-Meier method.
Proportion of Patients With a Toxic Event, Graded According to NCI CTCAE Version 4.03
时间窗: Up to 2 years
The reported output is the proportion of patients that had a toxic event along with the associated 90% Wilson's confidence interval.
次要结局
- Progression Free Survival (Phase II)(Up to 2 years)
- Proportion of Patients With a Response(Up to 2 years)
- Effects the Study Drug Combination Has on Participants(Day 1 of course 1 (before selinexor administration, 1, 2, 4 and 8 hours after selinexor administration) and days 2, 3 and 8)
研究者
Mohammed Najeeb Al Hallak
Principal Investigator
Barbara Ann Karmanos Cancer Institute